Head-to-head evidence
Camizestrant vs Giredestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Camizestrant
Marketed by AstraZeneca
NCT04588298 · Phase 2 · completed
Although participants were randomized among camizestrant dose groups, the study was open-label and had no placebo or active comparator; the primary endpoint was a surrogate biomarker, change in tumor ER expression, rather than a clinical outcome. Reported ER expression decreased across groups, but there was no controlled primary endpoint comparison to establish treatment benefit.
Next expected readout: April 2027 · NCT05774951 (registry estimate)
Giredestrant
Developed by Roche
NCT04436744 · Phase 2 · completed
This was a randomized but unblinded trial of 221 patients using a tumor biomarker (Ki67), rather than a hard clinical outcome such as tumor response or survival, as its primary measure; the giredestrant combination produced a statistically significant reduction in this biomarker compared with the anastrozole combination.
Next expected readout: July 2027 · NCT03332797 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Giredestrant's landscape